ILCN Industry Connections - ILCN.org (ILCN/WCLC)

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

SPONSORED CONTENT: Industry-supported content is provided by IASLC as a sponsor benefit.
The content has not been reviewed by IASLC and does not necessarily reflect the views or positions of IASLC.

SPONSORED CONTENT: Industry-supported content is provided by IASLC as a sponsor benefit. The content has not been reviewed by IASLC and does not necessarily reflect the views or positions of IASLC.

August 7, 2026

Medical Crossfire^®: ADCs and Bispecifics in Lung Cancer, Hype, Hope, or a New Standard of Care?

September 12, 2026 10:30 AM – 11:30 AM KST (Korean Time) | Seoul, South Korea Overview: ADCs and bispecific antibodies are rapidly changing the treatment landscape in thoracic oncology. In NSCLC, several ADCs and bispecific antibodies are already reshaping established treatment paradigms. In SCLC, novel bispecific T-cell engagers and ADCs are driving meaningful advances in…

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer, Hype, Hope, or a New Standard of Care?

Medical Crossfire^®: ADCs and Bispecifics in Lung Cancer, Hype, Hope, or a New Standard of Care?